David Marin

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Stem Cell Transplantation

The University of Texas MD Anderson Cancer Center

David Marin is a Professor at The University of Texas MD Anderson Cancer Center. A senior researcher in hematology and oncology, his work focuses on clinical stem cell transplantation, cellular therapy, and immunology, with particular emphasis on graft-versus-host disease prophylaxis and prognostic stratification in myeloid malignancies. His recent investigations include CAR NK-cell engineering to overcome antigen downregulation in multiple myeloma, regulatory checkpoints in NK-cell signaling, and the impact of TP53-mutant variant allele frequency on transplant outcomes in MDS/AML. He has also examined disparities in allograft access and long-term outcomes in FLT3-mutated acute myeloid leukemia. His findings have appeared in Nature, Blood Advances, and Haematologica.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

David Marin

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

hematology medicine oncology cell transplantation immunology hematological malignancies clinical transplantation transplantation medicine stem cell transplantation leukemia bone marrow transplantation regenerative medicine pharmacology organ transplantation cellular therapy myeloid neoplasia cancer research medicinal research cell therapy cancer treatment dermatology outcomes research pharmacotherapy cancer care oncogenes chronic myeloid leukemia cancer immunotherapy stem cell research lymphoid neoplasia stem-cell therapy laboratory medicine graft survival hepatology molecular diagnostics cytogenetics multiple myeloma cancer biology acute myeloid leukemia hemostasis experimental medicine transplantation proceeding transplant surgery liver transplantation cord blood graft rejection hla typing clinical immunology therapeutic efficacy myelodysplastic syndrome clinical mycology adaptive immune system cancer genetics chronic myeloid leukaemia cellular immune responses older patients anti-cancer agents novel therapies chronic phase cancer management disease progression cml patients acute lymphoblastic leukemia clinical evidence histocompatibility tyrosine kinase inhibitors vascular biology immunohaematology malignant blood disorders complete cytogenetic response hematologic malignancies long-term outcomes transfusion medicine imatinib mesylate cord blood transplantation post-transplantation cyclophosphamide tumor targeting

Notable Scholarly Works

Notable Federal Grants

Collaborators

Development of a Pilot Program to Reduce Nitazoxanide Utilization at a Major Cancer Center in Patients With Discordant Norovirus Testing. Transplantation and Cellular Therapy (2026)

infectious diseasesdiscordant norovirus testingmajor cancer centerclinical epidemiologycancer researchinfectious diseases (medical specialty)jama oncologymedicinemedical virologyreduce nitazoxanide utilizationoncologyvirus eradication

Abstract 6396: Crem is a Regulatory Checkpoint of Car and Il-15 Signaling in Nk Cells. Cancer Research (2025)

Hind RafeiRafet BasarSunil AcharyaYu-Sung HsuPinghua LiuDeqiang ZhangQingnan LiangVakul MohantyRanjan UpadhyayPing LiPravin PhadatareMerve DedeDonghai XiongCorry JonesMay DaherAna Karen Nunez CortesMayra ShanleyBin LiuSadie M. MoseleyPatrick ZhangDexing FangPinaki BanerjeeNadima UpretyYe LiRejeena ShresthaXinhai WanHong ShenVernikka WoodsApril GilbertSeema RawalJinzhuang DouYukun TanJeong-Min ParkFrancia Reyes SilvaAlexander BiederstädtMecit KaplanXin Ru JiangInci BiederstädtSilvia TibertiMadison MooreJingling JinLuis Muniz-FelicianoPaul LinGary M. DeyterNatalie W. FowlkesAbhinav JainDavid MarinKen ChenElizabeth ShpallKatayoun Rezvani

nk cellscancer researchcancer biologyregulatory checkpoint

Administration of Off-The-Shelf, Expanded, Most Closely Hla Matched, Third Party Viral Specific T Cells for the Therapy of Adenovirus Related Disease in Adult Immunocompromised Patients.. Blood (2025)

infectious diseasesvirologycell therapyadult immunocompromised patientsantiviral responsesimmunologycell transplantationimmunotherapycellular therapyantiviral therapyadenovirus related diseaseimmunity (medicine)medicinemedical virology

Allogeneic Stem Cell Transplant for T-Prolymphocytic Leukemia: A Single Center Analysis. Blood (2025)

cell therapyimmunologystem cellscell transplantationhematologycellular therapybone marrow transplantationadult t-cell leukemia-lymphomamedicineclinical transplantationstem cell transplantationsingle center analysisleukemiat-prolymphocytic leukemia

Cd70-Targeting Car Nk Cells Overcome Bcma Downregulation and Improve Survival in High-Risk Multiple Myeloma Models. Blood Cancer Discovery (2025)

oncogenescancer immunotherapyimmunologycell biologycell transplantationimmunotherapycellular therapyhematological malignanciesimmune responsesimmunity (medicine)cancer cellsimmune checkpoint inhibitorsimprove survival

Clonal Dynamics of Flt3-Itd Positive Acute Myeloid Leukemia Following Relapse After Allogeneic Stem Cell Transplantation. Blood (2025)

pathologyhaematopoiesisstem cell researchimmunologycell biologycell transplantationhematologybone marrow transplantationhematological malignanciesstem cell transplantationleukemiaclonal dynamicsmyeloid neoplasia

Crem is a Regulatory Checkpoint of Car and Il-15 Signalling in Nk Cells. Nature (2025)

Hind RafeiRafet BasarSunil AcharyaYu-Sung HsuPinghua LiuDeqiang ZhangToszka BohnQingnan LiangVakul MohantyRanjan UpadhyayPing LiPravin PhadatareMerve DedeDonghai XiongHuihui FanCorry Mathew JonesSebastian KunzMay DaherAna Karen Nunez CortesMayra ShanleyBin LiuSadie Mae MoseleyChenyu ZhangDexing FangPinaki BanerjeeNadima UpretyYe LiRejeena ShresthaXinhai WanHong ShenVernikka WoodsApril Lamour GilbertSeema RawalJinzhuang DouYukun TanJeong-Min ParkFrancia Reyes SilvaAlexander BiederstädtMecit KaplanXin Ru JiangInci BiederstädtBijender KumarSilvia TibertiMadison MooreJingling JinRyan Z YangLuis Muniz-FelicianoSamuel RosemorePaul LinGary M DeyterNatalie Wall FowlkesAbhinav K JainDavid MarinAnirban MaitraKen ChenTobias BoppElizabeth J ShpallKatayoun Rezvani

pathologyliver physiologystem cell researchgliomasdermatologypharmacologytherapeutic targetsnk cellsvascular biologytumor biologynovel therapiesgene expressionmedicinal researchcancer biologytumor heterogeneityinflammationviral persistenceleukemiatherapeutic efficacyregulatory checkpoint

Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (Ptcy)-Based Graft-Versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy (2025)

graft-versus-host disease prophylaxisorgan transplantationtranslational medicineimmunologycell transplantationgraft rejectionpost-transplant cyclophosphamidemedicineclinical transplantationallograft accesstransplantation medicine

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. Transplantation and Cellular Therapy (2025)

cell replacement therapiesimprove transplant outcomesorgan transplantationcell transplantationhematologybone marrow transplantationthiotepa myeloablative conditioningmedicinepharmacologyclinical transplantationclinical researchpharmacotherapystem cell transplantationleukemiamyeloid neoplasia

Guadecitabine Improved Relapse-Free Survival in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients After Transplant: Phase II Results From a Single Center. Haematologica (2025)

cell replacement therapiesradiation oncologyrelapse-free survivalorgan transplantationhematological malignancieshematologybone marrow transplantationphase ii resultscancer researchmedicineclinical transplantationsingle centerleukemiaoncologymyeloid neoplasiatransplantation medicine